Core Viewpoint - Heptares Therapeutics has announced a long-term global strategic collaboration and licensing agreement with Bristol-Myers Squibb to co-develop next-generation multispecific antibody therapies [1] Group 1: Financial Terms - Heptares Therapeutics will receive a total payment of $90 million as part of the agreement [1] - If Bristol-Myers Squibb chooses to advance all potential projects, Heptares could receive up to $1.035 billion in development and commercial milestone payments [1] - Additionally, Heptares will earn tiered royalties based on future product net sales [1] Group 2: Market Reaction - Following the announcement, Heptares' stock opened slightly higher but subsequently declined, experiencing a drop of over 5% at one point [1] - As of the latest update, the stock is down 2.08%, trading at HKD 12.72, with a trading volume of HKD 36.45 million [1]
和铂医药-B仍跌2% 与百时美施贵宝达成全球战略合作 潜在收益超10亿美元